Neuropace INC Form 4 insider transactions

Martha Morrell, Chief Medical Officer of NeuroPace Inc., reports the disposition of 237 shares of common stock to cover tax obligations.

Chief Medical Officer Martha Morrell reports acquisition of stock and option awards in NeuroPace Inc.

Rebecca Kuhn, CFO of NeuroPace Inc, reports the acquisition of 11,700 shares of common stock and 19,850 stock options on March 10, 2025.

NeuroPace's CEO, Joel Becker, reports the acquisition and disposal of company stock and stock options.

Chief Medical Officer Martha Morrell of NeuroPace Inc. reports disposition of shares to cover tax obligations.

Rebecca Kuhn, CFO of NeuroPace Inc, reports the disposition of 1,337 shares of common stock to cover tax obligations.

Rebecca Kuhn, CFO of NeuroPace Inc, disposed of 1,430 shares of common stock on February 27, 2025, to cover tax obligations arising from equity awards.

Martha Morrell, Chief Medical Officer of NeuroPace Inc., disposed of 1,430 shares of common stock to cover tax obligations.

Chief Medical Officer Martha Morrell of NeuroPace Inc. sold shares of common stock on February 21, 2025, under a pre-arranged 10b5-1 trading plan.

Martha Morrell, Chief Medical Officer of NeuroPace Inc., exercised stock options and acquired 50,000 shares of common stock at $0.026 per share on February 12, 2024.

Chief Medical Officer Martha Morrell reports transactions involving NeuroPace Inc. common stock and derivative securities, resulting in adjustments to her beneficial ownership.

Rebecca Kuhn, CFO of NeuroPace Inc, reports multiple transactions involving the disposal of common stock to cover tax obligations, resulting in a decrease in her direct holdings.

KCK LTD., a 10% owner of NeuroPace Inc, reports the sale of 5,270,845 shares of common stock at a price of $9.4 per share on February 20, 2025.

NeuroPace's Chief Medical Officer, Martha Morrell, sold a total of 300 shares of common stock under a pre-arranged 10b5-1 trading plan.

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, sold 3,200 shares of common stock at an average price of $15.01 per share under a pre-arranged 10b5-1 trading plan.

R Scott Huennekens, a director of NeuroPace Inc, acquired 15,507 stock options on January 6, 2025.

KCK LTD., a 10% owner of NeuroPace Inc, reports selling shares of common stock in two separate transactions on October 23 and October 25, 2024.

KCK LTD., a 10% owner of NeuroPace Inc, disposed of 4,082 shares of common stock at a price of $6.0885 per share on October 22, 2024.

KCK LTD., a 10% owner of NeuroPace Inc, reports selling shares of common stock in two separate transactions on October 18 and October 21, 2024.

KCK LTD., a 10% owner of NeuroPace Inc, has been gradually reducing its holdings through a series of transactions between October 3rd and October 17th, 2024.

KCK LTD., a 10% owner of NeuroPace Inc, has been gradually reducing its holdings through a series of transactions between August 30, 2024, and October 2, 2024.

Director Renee Ryan acquired 17,774 stock options in NeuroPace Inc. on June 7, 2024, according to a Form 4 filing.

Director Lisa Andrade acquired stock options in NeuroPace Inc. on June 7, 2024, according to a Form 4 filing.

Director Rakhi Kumar acquired stock options in NeuroPace Inc. on June 7, 2024, according to a Form 4 filing with the SEC.

Frank M. Fischer, a director of NeuroPace Inc., acquired stock options for 17,774 shares of common stock on June 7, 2024.

Director Uri Geiger acquired 17,774 stock options in NeuroPace Inc. on June 7, 2024, according to a Form 4 filing.

Director Joseph Lacob acquired stock options in NeuroPace, Inc. on June 7, 2024.

OrbiMed Advisors LLC, a significant shareholder of NeuroPace Inc, has sold a portion of its holdings in a series of transactions between May 1st and May 3rd, 2024.

OrbiMed Advisors LLC reports the sale of 1,781 shares of NeuroPace Inc (NPCE) at $14.06 per share on April 24, 2024, while still indirectly holding a significant number of shares.

OrbiMed Advisors LLC, a significant shareholder of NeuroPace Inc, has reported the sale of common stock in a series of transactions between April 19 and April 23, 2024.